Moderna’s novel coronavirus vaccine (mRNA-1273) is a front-running candidate to be one of the first available to market. If successful, the vaccine would also be the world’s ...
The U.S. Food and Drug Administration (FDA) recently approved Gilead’s antiviral Remdesivir for emergency use authorization (EUA) as a treatment for COVID-19 in severe stages. ...
Through partnerships with the world’s premier investment research organizations, Visible Alpha enhances the investment research process by extracting meaningful value from key sell-side assets, including analyst models, research reports and corporate access events. Our deep consensus data provides a quick understanding of the sell-side view on companies and industries at a level of granularity, timeliness and interactivity that has never before been possible.
Facebook
LinkedIn
Twitter© 2022 Visible Alpha, LLC. All rights reserved.
